###begin article-title 0
###xml 53 67 53 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L/SMARCA1 </italic>
Characterization of novel isoforms and evaluation of SNF2L/SMARCA1 as a candidate gene for X-linked mental retardation in 12 families linked to Xq25-26
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MeCP2</italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSK2 </italic>
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JARID1C</italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATRX</italic>
###xml 440 446 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 553 561 <span type="species:ncbi:9606">patients</span>
Mutations in genes whose products modify chromatin structure have been recognized as a cause of X-linked mental retardation (XLMR). These genes encode proteins that regulate DNA methylation (MeCP2), modify histones (RSK2 and JARID1C), and remodel nucleosomes through ATP hydrolysis (ATRX). Thus, genes encoding other chromatin modifying proteins should also be considered as disease candidate genes. In this work, we have characterized the SNF2L gene, encoding an ATP-dependent chromatin remodeling protein of the ISWI family, and sequenced the gene in patients from 12 XLMR families linked to Xq25-26.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 11 21 11 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
We used an in silico and RT-PCR approach to fully characterize specific SNF2L isoforms. Mutation screening was performed in 12 patients from individual families with syndromic or non-syndromic XLMR. We sequenced each of the 25 exons encompassing the entire coding region, complete 5' and 3' untranslated regions, and consensus splice-sites.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
The SNF2L gene spans 77 kb and is encoded by 25 exons that undergo alternate splicing to generate several distinct transcripts. Specific isoforms are generated through the alternate use of exons 1 and 13, and by the use of alternate donor splice sites within exon 24. Alternate splicing within exon 24 removes a NLS sequence and alters the subcellular distribution of the SNF2L protein. We identified 3 single nucleotide polymorphisms but no mutations in our 12 patients.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
Our results demonstrate that there are numerous splice variants of SNF2L that are expressed in multiple cell types and which alter subcellular localization and function. SNF2L mutations are not a cause of XLMR in our cohort of patients, although we cannot exclude the possibility that regulatory mutations might exist. Nonetheless, SNF2L remains a candidate for XLMR localized to Xq25-26, including the Shashi XLMR syndrome.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 810 815 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATRX </italic>
###xml 986 987 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1151 1152 1143 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1173 1178 1165 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSK2 </italic>
###xml 1295 1296 1287 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1297 1298 1289 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1339 1344 1331 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MeCP2</italic>
###xml 1407 1408 1399 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1442 1443 1434 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1444 1445 1436 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1467 1472 1459 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PHF6 </italic>
###xml 1509 1511 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1515 1521 1507 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNF41 </italic>
###xml 1522 1524 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1527 1533 1519 1525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNF81 </italic>
###xml 1534 1536 1526 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1543 1551 1535 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JARID1C </italic>
###xml 1552 1554 1544 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 405 412 <span type="species:ncbi:9606">patient</span>
###xml 1114 1122 <span type="species:ncbi:9606">patients</span>
The isolation of genes underlying X-linked mental retardation (XLMR) disorders has been hampered, in part, by the broad phenotypic variability observed in patients that restricts linkage analysis to large single families or instances where a specific trait facilitates phenotypic splitting. More recently, the use of large scale genomic methods including comparative genome hybridization (CGH) arrays and patient sequencing projects has increased the identification rate of XLMR disease genes. Surprisingly, each gene identified accounts for a small proportion of cases and there remain many conditions for which a gene has not been identified. Nonetheless, several trends have emerged. These include the identification of XLMR genes encoding proteins that modulate chromatin structure [1]. The cloning of the ATRX gene as the cause of the alpha-thalassemia mental retardation (ATR-X) syndrome established the paradigm for chromatin remodeling proteins in neurodevelopmental disorders [2]. This gene, encoding a SWI/SNF-like protein, is also mutated in other severe XLMR syndromes lacking alpha-thalassemia and in patients with mild-to-moderate XLMR [3]. Subsequently, the RSK2 gene encoding a histone kinase was identified as the causative gene for Coffin-Lowry syndrome and non-specific XLMR [4,5], and the methyl-CpG-binding protein 2 (MeCP2) gene was identified as the causative gene for Rett syndrome [6] and other non-specific male MR [7-9]. More recently, the PHF6 (Borjeson-Forssman-Lehmann syndrome;[10]), ZNF41 [11], ZNF81 [12], and JARID1C [13] genes have also been implicated in XLMR and have roles in transcriptional regulation and/or chromatin remodeling. Taken together, these studies suggest that additional chromatin interacting proteins whose genes reside on the X chromosome should be considered as disease candidates for both syndromal and non-specific XLMR disorders.
###end p 11
###begin p 12
###xml 81 82 81 82 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 91 94 91 94 <underline xmlns:xlink="http://www.w3.org/1999/xlink">SWI</underline>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 138 149 138 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2H </italic>
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2h </italic>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2h </italic>
###xml 407 413 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 596 606 596 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">engrailed </italic>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1069 1075 1069 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 1240 1245 1240 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L</italic>
###xml 4 14 <span type="species:ncbi:7227">Drosophila</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 138 148 <span type="species:ncbi:7227">Drosophila</span>
###xml 297 303 <span type="species:ncbi:10090">murine</span>
###xml 528 533 <span type="species:ncbi:9606">human</span>
###xml 1018 1022 <span type="species:ncbi:10090">mice</span>
The Drosophila ISWI gene was identified as a distinct SWI/SNF subclass named the Imitation SWI (ISWI) family [14]. Two human orthologs of Drosophila ISWI (dISWI) have been described, SNF2H (SMARCA5) which maps to 4q31.1 and SNF2L (SMARCA1) which maps to Xq25-26 [15,16]. Moreover, analysis of the murine Snf2h and Snf2l genes demonstrated that Snf2h was expressed in proliferating neuroblast layers whereas Snf2l expression was enhanced in differentiating neuronal populations [17]. Indeed, purification of the SNF2L-containing human NURF complex demonstrated that it regulated expression of the engrailed genes, which are important in mid/hind-brain development [18]. In addition, the latter study also demonstrated that SNF2L could promote neuronal differentiation when expressed ectopically in neuroblasts [18]. SNF2L was also found to be a component of a second chromatin remodeling complex, called CERF that contains the CECR2 protein, a transcription factor involved in neurulation and a cause of exencephaly in mice when mutated [19]. These studies suggest that SNF2L is an excellent candidate gene for the cause of XLMR. In this study, we have characterized multiple splice forms and examined 12 families with XLMR for mutations in SNF2L.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Reverse Transcription-PCR
###end title 14
###begin p 15
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 556 562 556 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 256 261 <span type="species:ncbi:9606">human</span>
For cell lines, total RNA was prepared from cell lines by acid phenol extraction of cell lysates [20]. Poly A+ RNA for reverse transcription was purified from total RNA using the PolyATtract mRNA Isolation System (Promega, Nepean, Ontario). Total RNA from human tissues and specific brain regions were obtained commercially (Applied Biosystems Canada, Streetsville, Ontario). Total RNA (2 ug) or Poly A+ RNA (100 ng) was reverse transcribed using Superscript RT (Invitrogen) and a combination of oligo dT and random hexamers. PCR reactions for analysis of SNF2L splice variants were at 94degreesC for 30 seconds, 53degreesC for 30 seconds and 72degreesC for 2 minutes for 35 cycles, followed by a final extension of 15 minutes at 72degreesC. For the 5' splice variants, the following primers were used: 5'UTR SNF2L1 Fwd, 5' CAAACTTGCTGCTAAAGCGCC 3'; 5'UTR SNF2L2 Fwd, 5' GGAATTCATGGAGCAGGACACTGC 3'; SNF2L5'splice variants Rev, 5'CACCAAGACAATTTTTAGTG 3'. For the NLS splice variants: SNF2L NLS Fwd, 5' GGAGGTCATGGAGTATTC 3' and SNF2L NLS Rev, 5'CAGTAGCTGACTCTGCTTTTCTTTTCTGTG 3'.
###end p 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Material
###end title 16
###begin p 17
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 597 605 <span type="species:ncbi:9606">Children</span>
DNA samples from 12 individuals affected with XLMR and previously mapped to a region encompassing the SNF2L gene were used for direct sequencing analysis. Samples from families F85-19 [21], F93-04, and F91-02 were provided by Drs. Ben Hamel and Hans van Bokhoven (University Hospital Nijmegen, Nijmegen, Netherlands). Samples K8045 [22], K8135 [23], K8320, K8395, K8725, K8895 [24], and K8923 were generously provided by Dr. Charles Schwartz (JC Self Research Institute, Greenwood Genetic Center, Greenwood South Carolina). The non-syndromic XLMR sample 24981 was provided by Dr. Judith Allanson (Children's Hospital of Eastern Ontario, Ottawa Ontario). The Pettigrew syndrome DNA sample was prepared from a commercially available EBV transformed lymphoblast cell line (GM12523; Coriell Cell Repository, Camden, NJ).
###end p 17
###begin title 18
Plasmid constructs
###end title 18
###begin p 19
###xml 241 244 241 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 250 253 250 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 388 391 388 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
The SNF2L NLS splice variants were cloned into the pcDNA3 expression plasmid (Invitrogen Canada Inc. Burlington, ON), each with an amino terminal tag encoding the FLAG epitope. Annealed primers encoding the FLAG epitope were inserted in the KpnI and EcoRI sites of the pcDNA3 plasmid. The 5' region encoding the amino terminus of the SNF2L2 splice variant (SNF2LB) was engineered with an EcoRI restriction site for cloning in frame with the FLAG epitope. The primers used were: FLAG-sense EcoRI, 5'-CCCACCATGGATTACAAGGATGACGACGATAAGG-3' and FLAG-antisense EcoRI, 5'-AATTCCTTATCGTCGTCATCCTTGTAATCCATGGTGGGGTAC-3'. The remainder of each cDNA (+ NLS or -NLS) was inserted in two additional cloning steps to construct plasmids encoding full length SNF2L proteins with and without a nuclear localization signal.
###end p 19
###begin title 20
Cell transfections and immunofluorescence
###end title 20
###begin p 21
###xml 177 179 177 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 406 408 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 124 130 <span type="species:ncbi:9913">bovine</span>
###xml 810 816 <span type="species:ncbi:10090">murine</span>
###xml 994 1000 <span type="species:ncbi:9793">donkey</span>
###xml 1006 1012 <span type="species:ncbi:10090">murine</span>
293HEK cells were cultured in EMEM (Eagle's Minimal Essential Medium, Wisent, St Bruno, Quebec) supplemented with 10% fetal bovine serum (FBS) in a humidified 95% air with 5% CO2 incubator at 37degreesC. One day prior to transfection, cells were plated on glass coverslips coated with poly D-lysine (100 mug/ml, Sigma, Oakville, Ontario) in 6 well tissue culture plates at a density of approximately 3 x 105 cells/well. Cells were transfected with 5 mug DNA [pcDNA3 control, pcDNA3 FLAG-SNF2LDeltaNLS, or pcDNA3 FLAG SNF2L] and the Lipofectamine 2000 reagent (Life Technologies, Burlington, Ontario) according to the manufacturer's protocol. After 48 hours, cells were fixed in cold ethanol/methanol (3:1) prior to blocking with 10% FBS diluted in PBS. Coverslips were incubated with diluted primary antibody (murine anti-FLAG monoclonal clone M2, 2 mug/ml, Sigma, Oakville, Ontario) for 1 hour at room temperature, washed and then incubated for 1 hour at room temperature with FITC-conjugated donkey-anti-murine IgG secondary antibody (Sigma) diluted 1:100 in PBS. Cell nuclei were counterstained with 1 mug/ml DAPI (Sigma) and images were captured using a Zeiss Axioplan 2 microcope outfitted with an AxioCam camera and AxioVision software.
###end p 21
###begin title 22
SNF2L Mutation Analysis
###end title 22
###begin p 23
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 518 519 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Genomic DNA from individuals affected with XLMR in each of the 12 families analyzed was used to amplify each exon of the SNF2L gene with forward and reverse primers that annealed to flanking intron sequences, approximately 100 bp from each exon/intron boundary (primer sequences available upon request). Genomic DNA from an individual unaffected by XLMR was the control for all PCR reactions. For each reaction, 100-200 ng DNA was combined with 1 muM each of forward and reverse PCR primers, 200 muM dNTPs, 2.5 mM MgCl2, 20 mM Tris-HCl pH 8.4, 50 mM KCl, and 1 unit Taq DNA polymerase in a volume of 100 mul. PCR reactions were incubated at 95degreesC for 40 seconds, 57degreesC for 40 seconds and 72degreesC for 3 minutes for 30 cycles, followed by a final extension of 15 minutes at 72degreesC. DNA obtained from PCR reactions was purified using the Qiaquick PCR Purification kit (Qiagen, Mississauga, Onatario) and sequenced using Perkin Elmer dye terminator and ABI automated sequencing. Sequences were aligned and compared to sequences obtained from the control DNA and sequence available in public databases to identify mutations.
###end p 23
###begin title 24
Results and Discussion
###end title 24
###begin p 25
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 282 292 282 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In silico </italic>
###xml 323 329 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 786 792 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1059 1066 1059 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2LA </italic>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2LB</italic>
###xml 1092 1099 1092 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2LB </italic>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1270 1277 1270 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2LA </italic>
###xml 1393 1394 1393 1394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1427 1434 1427 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2LB </italic>
###xml 1489 1491 1489 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1498 1503 1498 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L</italic>
###xml 1726 1728 1726 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 374 379 <span type="species:ncbi:10090">mouse</span>
###xml 384 389 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
###xml 631 636 <span type="species:ncbi:10090">mouse</span>
###xml 780 785 <span type="species:ncbi:9606">human</span>
###xml 975 980 <span type="species:ncbi:9606">human</span>
###xml 1128 1134 <span type="species:ncbi:10090">murine</span>
###xml 1222 1227 <span type="species:ncbi:9606">human</span>
###xml 1465 1471 <span type="species:ncbi:10090">murine</span>
###xml 1532 1536 <span type="species:ncbi:10090">mice</span>
###xml 1573 1579 <span type="species:ncbi:9606">humans</span>
###xml 1661 1666 <span type="species:ncbi:9606">human</span>
###xml 1692 1697 <span type="species:ncbi:9606">human</span>
Spatial and temporal expression studies of the Snf2l gene in mice and the purification of two human SNF2L-containing complexes have both suggested that the SNF2L protein may have an important role in neurodevelopment and that the SNF2L gene is a strong XLMR candidate gene [17-19]. In silico analysis demonstrated that the SNF2L gene (NM_003069) is highly conserved between mouse and human with a common intron/exon pattern containing 25 exons spanning ~77 kb along the X chromosome within Xq25 (Figure 1A and data not shown). However, the human cDNA and predicted protein sequences showed several significant discrepancies to the mouse Snf2l sequence (NM_053123) that required characterization, prior to mutation studies [16,17]. Indeed, we previously reported the presence of a human SNF2L variant (SNF2L+13) containing a non-conserved in-frame exon within the SNF2 catalytic domain that abolishes chromatin remodeling activity [25]. In addition, Okabe et al. reported two human cDNA clones with disparate 5' ends [16]. We will refer to these two clones as SNF2LA and SNF2LB, respectively. SNF2LB aligns with the start of the murine cDNA sequence and corresponds to a transcript that would initiate within exon 1 of the human genomic sequence (Figure 1B). The shorter SNF2LA isoform results from transcription that initiates within exon 2. The corresponding proteins differ in size at the NH2-terminus by 78 amino acids with SNF2LB corresponding to the published murine sequence (Figure 1B). The SNF2LA isoform was not present in mice suggesting that it may be unique to humans. Using RT-PCR, we detected the corresponding transcripts for both 5' variants in human fetal brain and multiple human neuronal cell lines (Figure 1C).
###end p 25
###begin p 26
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genomic organization and 5' transcript variants of the human <italic>SNF2L </italic>gene</bold>
###xml 73 74 73 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 371 372 371 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 390 397 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2LA </italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L</italic>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 542 548 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 562 567 562 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L</italic>
###xml 695 696 695 696 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 536 541 <span type="species:ncbi:10090">mouse</span>
###xml 673 679 <span type="species:ncbi:10090">murine</span>
###xml 767 772 <span type="species:ncbi:9606">human</span>
###xml 969 974 <span type="species:ncbi:9606">human</span>
Genomic organization and 5' transcript variants of the human SNF2L gene. A. Schematic diagram showing the 25 exons (dark boxes; exon 13 is an open box) of the human SNF2L gene (top). Below is a schematic diagram of the SNF2L transcript showing the ORF (open box) and the location of the motifs that comprise the SNF2 domain (blue boxes) and the SANT domains (red boxes). B. The 5' variants SNF2LA and SNF2LB provide alternative initiation codons and encode two forms of SNF2L with different amino-termini. They are shown aligned to the mouse Snf2l sequence. The SNF2LB transcript encodes a protein with an amino-terminus similar in length and amino acid composition to the murine Snf2l protein. C. RT-PCR analysis showing that both transcript variants are present in human cell lines and fetal brain tissue examined. The helicase I/Ia domain served as control amplification. Lane 1, 293 cells; lane 2, SH-SY5Y cells; lane 3, NT2 cells; lane 4, hNT neurons; and lane 5, human fetal brain. M, molecular weight marker.
###end p 26
###begin p 27
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1063 1065 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1190 1197 1186 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1374 1376 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 199 204 <span type="species:ncbi:9606">human</span>
###xml 238 243 <span type="species:ncbi:10090">mouse</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 972 977 <span type="species:ncbi:10090">mouse</span>
In addition to the variation at the amino-terminus, the human and mouse amino acid sequences also differed at their carboxyl-terminus following Blast tool analysis. The last seven amino acids of the human sequence were not present in the mouse SNF2L protein sequence, but instead were replaced by 23 unique residues (Figure 2A). RT-PCR analysis demonstrated that both 3'-end variants could be detected in a variety of human cell lines, tissues and specific brain regions with the NLS-containing isoform representing the predominant species (Figure 2B). Sequencing demonstrated that the two transcripts are generated by alternative splicing of exons 24 and 25. Inclusion of exons 24 and 25 result in a shorter peptide due to a stop codon located at the start of exon 25. We called this variant SNF2LDeltaNLS. Alternative use of splice sites within exons 24 and 25 removes 100 bp and generates a transcript that contains an additional 23 amino acids similar to the reported mouse protein (and herein called SNF2L). More importantly, we used the PredictNLS program [26] to determine that this alternatively spliced region contained a putative NLS sequence. To verify the importance of the NLS in vivo, we transiently transfected 293 HEK cells with FLAG-epitope tagged SNF2L or SNF2LDeltaNLS and detected the expressed protein by indirect immunofluorescence. As shown in Figure 2C, SNF2LDeltaNLS localized exclusively in the cytoplasm whereas SNF2L was present in the nucleus.
###end p 27
###begin p 28
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alternative splicing of exons 24 and 25 generates nuclear and cytoplasmic isoforms of SNF2L</bold>
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 425 426 421 422 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1090 1091 1086 1087 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 639 644 <span type="species:ncbi:9606">human</span>
###xml 760 765 <span type="species:ncbi:9606">human</span>
###xml 791 796 <span type="species:ncbi:9606">human</span>
###xml 962 967 <span type="species:ncbi:9606">human</span>
Alternative splicing of exons 24 and 25 generates nuclear and cytoplasmic isoforms of SNF2L. Alternative splicing of the SNF2L gene at the 3' end generates a transcript containing either the full sequence of exons 24 and 25, which encodes a shorter form of SNF2L without a nuclear localization signal (SNF2LDeltaNLS), or a transcript lacking 100 bp that encodes for a larger protein isoform (SNF2L) with an NLS (underlined). B. RT-PCR analysis demonstrated that both 3' variants are present in most cells and tissues examined, while the NLS isoform is predominant. M, marker; -D, no DNA template; -RT, no reverse transcriptase. Lanes 1-5, human cell lines and fetal brain sample as follows: 1, 293-HEK cells; 2, SH-SY5Y cells; 3, NT2 cells; 4, hNT neurons; 5, human fetal brain. Lanes 6-13, human brain regions including: 6, amygdala; 7, basal ganglia; 8, caudate nucleus; 9, cerebellum; 10, frontal cortex; 11, hippocampus; 12, pons; 13, thalamus. Lanes 14-20, human tissue samples including: 14, heart; 15, kidney; 16, liver; 17, ovary; 18, placenta; 19, skeletal muscle; and 20, testes. C. Indirect immunofluorescence imaging of 293 HEK cells transfected with FLAG-epitope tagged SNF2LDeltaNLS and SNF2L were stained with anti-flag antibody (green) or DAPI (blue). Note that SNF2LDeltaNLS encodes a protein that is localized exclusively in the cytoplasm while SNF2L is expressed only in the nucleus (arrows point to nuclei of transfected cells).
###end p 28
###begin p 29
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
The SNF2L gene undergoes alternative splicing at multiple sites to generate a wide number of different isoforms. Some of these isoforms will affect the activity of the protein. For example, the inclusion of exon 13 abolishes the chromatin remodeling activity [25], and the altered splicing within exons 24/25 removes the NLS resulting in cytoplasmic localization. In the latter case, the SNF2LDeltaNLS variant was detected in most tissues examined, suggesting that the cytoplasmic isoform of SNF2L may fulfill an alternative role to the chromatin remodeling function of the nuclear isoforms. Alternatively, it could represent a SNF2L dominant negative protein that sequesters other components of the chromatin remodeling complex in the cytoplasm. As such, it will be important to further explore the function of these novel SNF2L isoforms to determine their specific roles, similar to work done with the SNF2L+13 variant. Indeed, with splicing occurring at the 5'-end of the gene (isoforms SNF2LA and B), the 3'-end of the gene (NLS or DeltaNLS) and encompassing exon 13 (+exon 13 or -exon 13) there are 8 possible isoforms of the SNF2L protein that can impinge on the function/activity of the protein.
###end p 29
###begin p 30
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 577 583 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 716 722 716 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 840 846 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 963 964 963 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1425 1431 1425 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNF2L </italic>
###xml 44 50 <span type="species:ncbi:10090">murine</span>
###xml 336 341 <span type="species:ncbi:10090">mouse</span>
###xml 571 576 <span type="species:ncbi:9606">human</span>
We have demonstrated that expression of the murine Snf2l gene increases during development in a manner that is coincident with neuronal maturation and synapse formation [17]. This expression profile is most prevalent in the hippocampus, dentate gyrus and the cerebellum and expression within these structures is maintained in the adult mouse [17]. Given that the hippocampus and dentate gyrus have been implicated in learning and memory, and that mutations in genes involved in chromatin remodeling or modification cause mental retardation, it prompted us to examine the human SNF2L gene as a candidate XLMR gene. DNA samples from 12 individuals affected with XLMR and previously mapped to a region encompassing the SNF2L gene were used for direct sequencing analysis. We sequenced each of the 25 exons and flanking intron sequences of the SNF2L gene and identified 3 different single nucleotide polymorphisms (SNPs), all located in untranslated sequences (Table 1). Screening of 100 unaffected individuals demonstrated that the SNP in the 5' UTR of exon 1 and the polymorphism in intron 13 (rs2274093) had frequencies of 13% and 15% respectively, in our control population. Conversely, the SNP in intron 18 was not found in our control DNA samples, but screening of the SNP database identified it as a polymorphism with a heterozygosity frequency of 0.093 (rs3736692). Overall, the SNP database contains 195 entries for the SNF2L gene including 5 in the coding region (exons 1, 10, 16, 17, and 20). The SNP within exon 20 is reported to have a heterozygosity value of 0.026 and would result in an Ala to Gly substitution. While we did not find this change in any of our families, future analysis of this gene should be wary of this polymorphism.
###end p 30
###begin p 31
Mutation analysis of 12 families linked to Xq25 revealed 3 SNPs
###end p 31
###begin p 32
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATRX</italic>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1199 1201 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1257 1263 1257 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snf2l </italic>
###xml 1235 1240 <span type="species:ncbi:10090">mouse</span>
###xml 1442 1457 <span type="species:ncbi:10090">transgenic mice</span>
Despite the absence of mutations in these families, SNF2L remains a logical candidate for XLMR localized to Xq25-26 because of (a) its similarity to ATRX, a SNF2-domain containing protein mutated in several XLMR disorders; (b) its high expression in the brain including areas important for learning and development; and (c) its ability to induce neuroblastoma cells to undergo differentiation when ectopically expressed [17,18]. In addition, SNF2L has been shown to regulate the engrailed genes, En-1 and En-2, both of which are important for mid/hind-brain development [27,28], the latter of which has been associated with autism in genetic linkage studies [29-31]. Given these criteria and the small sample size available for mutation analysis, other syndromes should be considered for screening, including the Shashi XLMR syndrome [32,33] and a family with syndromal XLMR and late-onset testicular failure (Cillier syndrome) [34] that both map to Xq26. In addition, there are 3 other syndromes (Wilson/MRXS12, Gustavson, and CMTX4/Cowchock-Fishbeck) and 8 MRX families (MRX 27, 35, 42, 62, 70, 71, 75, and 82) that map to this region that should also be considered in future screening endeavors [35]. The generation of a transgenic mouse ablated for the Snf2l gene should provide valuable phenotypic insight for its potential involvement in specific XLMR disorders. Together, the analysis of additional samples and the characterization of transgenic mice should define whether the SNF2L gene is a cause of mental retardation.
###end p 32
###begin title 33
Conclusion
###end title 33
###begin p 34
###xml 282 290 <span type="species:ncbi:9606">patients</span>
We have shown that there are multiple SNF2L isoforms that result from alternative splicing of the gene. How these different isoforms are spatially and temporally regulated and defining their specific role during neural development remains to be established. In our collection of 12 patients with XLMR linked to Xq25-26, we did not identify any mutations within the coding region. However, we cannot exclude intronic mutations (outside of the consensus splice sites) that would affect alternative splicing and hence the expression levels of the different isoforms. Similarly, we cannot exclude mutations in regulatory regions in the 12 families screened for mutations in this gene. Alternatively, our failure to identify mutations may arise from (1) the small sample size which may have prevented us from ascertaining a family with a mutation in this gene, or (2) the possibility that mutations in SNF2L could cause a more severe phenotype that may be lethal in males. Indeed, SNF2L remains a candidate XLMR gene for Xq25-26 linked XLMR families including the Shashi syndrome as well as in sporadic mental retardation cases.
###end p 34
###begin title 35
Competing interests
###end title 35
###begin p 36
The author(s) declare that they have no competing interests.
###end p 36
###begin title 37
Authors' contributions
###end title 37
###begin p 38
###xml 192 197 <span type="species:ncbi:9606">human</span>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
MAL identified the various SNF2L isoforms, generated the preliminary RT-PCR data and performed the immunofluorescence experiments. MAMT extended the RT-PCR experiments to include the multiple human tissues and brain regions. PL and DV performed the sequence analysis of the XLMR patients. AD prepared the initial figures and wrote the first draft of the manuscript. DJP designed the study, participated in its execution and coordination and wrote the final manuscript. All authors have read and approved the final manuscript.
###end p 38
###begin title 39
Pre-publication history
###end title 39
###begin p 40
The pre-publication history for this paper can be accessed here:
###end p 40
###begin p 41

###end p 41
###begin title 42
Acknowledgements
###end title 42
###begin p 43
###xml 115 122 <span type="species:ncbi:9606">patient</span>
The authors would like to thank Drs. Allanson, Hamel, Schwartz, and Van Bokhoven for their generosity in providing patient DNA samples. This work was supported by grants from the Ontario Mental Health Foundation and the Neuromuscular Research Partnership (JNM-78384), an initiative of the ALS Society of Canada, Muscular Dystrophy Canada, and the Canadian Institutes of Health Research.
###end p 43
###begin article-title 44
Monogenic causes of X-linked mental retardation
###end article-title 44
###begin article-title 45
Syndromal mental retardation due to mutations in a regulator of gene expression
###end article-title 45
###begin article-title 46
Molecular-clinical spectrum of the ATR-X syndrome
###end article-title 46
###begin article-title 47
Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities
###end article-title 47
###begin article-title 48
Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome
###end article-title 48
###begin article-title 49
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2
###end article-title 49
###begin article-title 50
A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males
###end article-title 50
###begin article-title 51
###xml 23 31 <span type="species:ncbi:9606">patients</span>
MECP2 mutation in male patients with non-specific X-linked mental retardation
###end article-title 51
###begin article-title 52
MECP2 is highly mutated in X-linked mental retardation
###end article-title 52
###begin article-title 53
Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome
###end article-title 53
###begin article-title 54
Mutations in the ZNF41 gene are associated with cognitive deficits: identification of a new candidate for X-linked mental retardation
###end article-title 54
###begin article-title 55
Zinc finger 81 (ZNF81) mutations associated with X-linked mental retardation
###end article-title 55
###begin article-title 56
Mutations in the JARID1C Gene, Which Is Involved in Transcriptional Regulation and Chromatin Remodeling, Cause X-Linked Mental Retardation
###end article-title 56
###begin article-title 57
###xml 39 49 <span type="species:ncbi:7227">Drosophila</span>
###xml 67 72 <span type="species:ncbi:4932">yeast</span>
Identification and characterization of Drosophila relatives of the yeast transcriptional activator SNF2/SWI2
###end article-title 57
###begin article-title 58
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 75 85 <span type="species:ncbi:7227">Drosophila</span>
Cloning and mapping of SMARCA5 encoding hSNF2H, a novel human homologue of Drosophila ISWI
###end article-title 58
###begin article-title 59
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 21 27 <span type="species:ncbi:9913">bovine</span>
###xml 90 95 <span type="species:ncbi:4932">yeast</span>
###xml 96 109 <span type="species:ncbi:4932">S. cerevisiae</span>
Cloning of human and bovine homologs of SNF2/SWI2: a global activator of transcription in yeast S. cerevisiae
###end article-title 59
###begin article-title 60
###xml 36 42 <span type="species:ncbi:10090">murine</span>
Cloning and characterization of the murine Imitation Switch (ISWI) genes: differential expression patterns suggest distinct developmental roles for Snf2h and Snf2l
###end article-title 60
###begin article-title 61
###xml 13 18 <span type="species:ncbi:9606">human</span>
Isolation of human NURF: a regulator of Engrailed gene expression
###end article-title 61
###begin article-title 62
CECR2, a protein involved in neurulation, forms a novel chromatin remodeling complex with SNF2L
###end article-title 62
###begin article-title 63
Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction
###end article-title 63
###begin article-title 64
Familial X-linked mental retardation and isolated growth hormone deficiency: clinical and molecular findings
###end article-title 64
###begin article-title 65
Spastic paraplegia with iron deposits in the basal ganglia: a new X-linked mental retardation syndrome
###end article-title 65
###begin article-title 66
A new X linked mental retardation (XLMR) syndrome with short stature, small testes, muscle wasting, and tremor localises to Xq24-q25
###end article-title 66
###begin article-title 67
X linked severe mental retardation, craniofacial dysmorphology, epilepsy, ophthalmoplegia, and cerebellar atrophy in a large South African kindred is localised to Xq24-q27
###end article-title 67
###begin article-title 68
###xml 39 44 <span type="species:ncbi:9606">human</span>
A tissue-specific, naturally occurring human SNF2L variant inactivates chromatin remodeling
###end article-title 68
###begin article-title 69
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Subtle cerebellar phenotype in mice homozygous for a targeted deletion of the En-2 homeobox
###end article-title 69
###begin article-title 70
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum
###end article-title 70
###begin article-title 71
Support for the homeobox transcription factor gene ENGRAILED 2 as an autism spectrum disorder susceptibility locus
###end article-title 71
###begin article-title 72
Association of the homeobox transcription factor, ENGRAILED 2, 3, with autism spectrum disorder
###end article-title 72
###begin article-title 73
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
The mouse Engrailed genes: a window into autism
###end article-title 73
###begin article-title 74
Shashi XLMR syndrome: report of a second family
###end article-title 74
###begin article-title 75
A unique form of mental retardation with a distinctive phenotype maps to Xq26-q27
###end article-title 75
###begin article-title 76
A new X-linked mental retardation (XLMR) syndrome with late-onset primary testicular failure, short stature and microcephaly maps to Xq25-q26
###end article-title 76
###begin article-title 77
XLMR genes: update 2007
###end article-title 77

